Ensartinib is a second-generation tyrosine kinase inhibitor (TKI) developed independently in China, which is superior to crizotinib in the treatment of anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC). In real-world investigations, no cases of organizing pneumonia (OP) have been reported among patients receiving enshatinib in NSCLC. Herein, we report a case of early OP in a 50-year-old woman who was initially treated with ensartinib for advanced NSCLC. After one month of treatment with ensartinib, chest CT found bilateral OP which improved after stopping ensartinib and using steroid drugs.
No takes yet. Share an insight, caveat, or question.
Xie et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: